Esophageal cancer: Loss of muscle mass represents a significant risk to survival

Esophageal cancer patients who suffer loss of muscle mass (sarcopenia) during neoadjuvant therapy (chemotherapy prior to surgery) survive, on average, 32 months less than patients with no sarcopenia, new research concludes.
Source: Feed4

Leave a Reply

Your email address will not be published. Required fields are marked *